Cellectis S.A.

CLLSNASDAQHealthcare● Active

$2.93

$-0.13(-4.25%)

Market Cap$294222138

P/E Ratio—

52W High$5.48

52W Low$1.327

Avg Volume41K

Open$2.97

Beta2.75

Free Cash Flow Financials Revenue

Cellectis S.A. (CLLS) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

CLLS · free cash flow · updated Jun 8, 2026

Core FCF metrics

CLLS · FCF · TTM · margin & CAGR

Free cash flow was −$42.5M for FY2025 (fiscal year ending 2025-12-31), down 317.7% year-over-year The FCF margin was -58.3%.

FY2025 Free Cash Flow−$42.5M▼ -317.7% YoY

Trailing 12M (TTM)−$40.1Mtrailing 4 quarters sum

FCF Margin-58.3%−$42.5M ÷ revenue

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

CLLS · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$40.1M(2M)−$42.5M▼ 317.7%-58.3%

FY2024$22.1M(3M)$19.5M▲ +175.6%47.0%

FY2023−$24.7M(1M)−$25.8M▲ +71.3%—

FY2022−$87.4M(2M)−$89.9M▲ +27.0%-468.9%

FY2021−$104.6M(19M)−$123.1M▲ +1.3%-405.7%

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

CLLS · P/FCF · FCF yield · FCF per share

Cellectis S.A. (CLLS) reported negative free cash flow of −$0.04B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

CLLS · cash flow statement · operating / investing / financing

For FY2025, Cellectis S.A. generated −$40.1M in operating cash flow and spent 2M in capital expenditures, yielding −$42.5M in free cash flow.

Operating Activities

−$40.1M

Cash from core business operations

2025-12-31

Investing Activities

−$29.6M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

−$16.2M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$40.1M) − |CapEx| (2M) = FCF (−$42.5M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

CLLS vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Cellectis S.A.YOU

CLLS

−$42.5M-317.7%-58.3%

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Cellectis S.A. (CLLS) reported free cash flow of −$42.5M for FY2025 (fiscal year ending 2025-12-31), down 317.7% year-over-year. The FCF margin was -58.3%.

Based on available data, Cellectis S.A. has maintained positive free cash flow for at least 2 fiscal year(s). FCF peaked at $50.3M in FY2014.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

CLLS free cash flow · 8 questions

Cellectis S.A. free cash flow was −$42.5M for FY2025, down 317.7% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$40.1M.

CLLS free cash flowCLLS FCFCLLS FCF 2025CLLS free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Cellectis S.A. · Cellectis S.A. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026